CNC 8-K Current Reports
CENTENE CORP - 393 current reports
CENTENE CORP 8-K Report, Executive Changes (Aug 17, 2026)
Centene Corporation (CNC) has announced a significant leadership transition in its finance department. Effective December 31, 2026, Chief Financial Officer Andrew Asher will retire from his role but will continue to support the company as a Strategic Advisor through the end of 2027 to ensure a smooth handover and assist with strategic initiatives. This transition is designed to leverage Mr. Asher's experience during a crucial period. To ensure continuity and bring in fresh expertise, Centene has appointed Christopher Neczypor as the successor CFO, effective January 1, 2027. Mr. Neczypor brings substantial financial and strategic experience, including prior CFO and Chief Strategy Officer roles at Lincoln National Corporation, and a background in investment management focused on the insurance sector. His appointment is accompanied by a comprehensive employment agreement outlining his compensation and responsibilities leading up to and following his official CFO tenure, including an initial Executive Vice President role starting September 1, 2026.
CENTENE CORP 8-K Report, Corporate Update (Jul 29, 2026)
Centene Corporation (CNC) has announced a partial redemption of its 4.25% Notes due December 15, 2027. The company intends to redeem $500,000,000 of these notes on August 13, 2026. This action will reduce the outstanding principal amount of the 2027 Notes to approximately $568,664,000 following the redemption. Investors holding these notes should be aware that their principal investment will be partially repaid at par plus any accrued interest up to the redemption date. This move signals a potential shift in Centene's capital structure or debt management strategy, and investors should monitor any further announcements regarding the use of cash or changes in debt levels.
CENTENE CORP 8-K Report, Financial Results (Jul 28, 2026)
Centene Corporation (CNC) filed an 8-K on July 28, 2026, primarily to disclose its financial results for the second quarter ended June 30, 2026, via a press release (Exhibit 99.1). While the specific financial details are not within this excerpt, the filing indicates that an earnings announcement has been made. Additionally, the company announced a change in its Board of Directors. Director Kenneth Burdick resigned from the Board and the Quality and Compliance Committee, effective July 28, 2026. His resignation was stated to be amicable and not due to any disputes. Following Mr. Burdick's resignation, Centene elected Paul Diaz to the Board, effective July 28, 2026, with his term extending to the 2027 annual meeting. Mr. Diaz brings extensive experience in the healthcare sector, having held leadership positions at Kindred Healthcare, Myriad Genetics, and currently serves as a Managing Partner at Cressey & Company. He has been appointed to serve on the Audit Committee and the Quality and Compliance Committee, adding valuable expertise to the company's governance.
CENTENE CORP 8-K Report, Executive Changes (Jun 22, 2026)
Centene Corporation (CNC) announced a change to its Board of Directors with the appointment of Lauren Tyler, effective June 19, 2026. The Board's size has been expanded from 9 to 10 members to accommodate this new director. Ms. Tyler brings extensive experience from her over two-decade tenure at JPMorgan Chase & Co., where she held senior roles including Global Head of Human Resources for its Asset & Wealth Management Division and Global Firmwide Chief Auditor. Her prior experience also includes serving as Global Firmwide Head of Investor Relations. This appointment is significant as Ms. Tyler is expected to contribute to key board committees, specifically the Audit Committee and the Compensation and Talent Committee, starting July 1, 2026. Her existing board memberships at Cencora, Inc. and Guardian Life further underscore her qualifications. Investors should note that Ms. Tyler's appointment does not involve any undisclosed arrangements or related party transactions, and she will be compensated under the company's standard non-employee director program.
CENTENE CORP 8-K Report, Executive Changes (May 15, 2026)
Centene Corporation (CNC) filed an 8-K on May 15, 2026, detailing the outcomes of its Annual Meeting of Stockholders held on May 12, 2026. The report confirms the election of all nine director nominees for a one-year term, with strong support across the board. Additionally, shareholders provided a non-binding advisory vote of approval for the company's executive compensation and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Of note, a shareholder proposal requesting an independent board chairman was not approved. The filing also clarifies the company's executive officer positions following recent appointments, with Sarah London continuing as CEO and key leadership roles in Medicaid, Medicare, and other operational areas outlined.
CENTENE CORP 8-K Report, Financial Results (Apr 28, 2026)
Centene Corporation (CNC) has filed an 8-K report on April 28, 2026, to announce its financial results for the first quarter ended March 31, 2026. The primary purpose of this filing is to provide investors with key financial performance data for the period. While the 8-K itself does not contain the detailed financial results, it references an attached press release (Exhibit 99.1) which serves as the primary source of this information. Investors should refer to the press release furnished as Exhibit 99.1 for comprehensive details on Centene's first-quarter performance. It's important to note that the information in this 8-K and its exhibits is considered "furnished" and not "filed" under the Securities Exchange Act of 1934. This means it is not subject to the same liability provisions as formally filed documents, although it is still a crucial source of timely information for market participants.
CENTENE CORP 8-K Report, Executive Changes (Mar 24, 2026)
Centene Corporation (CNC) announced a key leadership transition within its finance department, effective March 18, 2026. Theodore Pienkos has been appointed as the new Corporate Controller and Chief Accounting Officer. Mr. Pienkos is a seasoned executive with a long tenure at Centene, having held various accounting and finance roles since 2011, including Deputy Corporate Controller since August 2024. His extensive experience, including his background as a CPA and former auditor at KPMG, positions him well to oversee the company's accounting functions. In parallel, Kate Casso, the former Corporate Controller and Chief Accounting Officer, has been appointed to the newly created role of Senior Vice President, Finance Operations and Innovation. This move reflects Centene's focus on leadership development and strategic innovation. Ms. Casso will leverage her deep understanding of the company, gained over two decades of service, to drive improvements in finance operations, data analytics, and innovation initiatives, while continuing to oversee critical finance teams. Investors can view these changes as positive steps towards strengthening financial oversight and fostering future growth.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 10, 2026)
Centene Corporation has filed an 8-K report on March 10, 2026, primarily to provide an update ahead of their presentation at the Barclays 28th Annual Global Healthcare Conference. The key takeaway for investors is the reaffirmation of the company's previously issued 2026 full-year financial guidance. Centene expects to achieve GAAP diluted earnings per share (EPS) greater than $1.98 and adjusted diluted EPS greater than $3.00, signaling confidence in their operational performance and outlook for the remainder of the fiscal year. In addition to reaffirming guidance, the report disclosed Centene's intention to partially redeem its outstanding 4.25% Notes due December 15, 2027. The company plans to redeem $1,000,000,000 in aggregate principal amount of these notes on March 25, 2026, with approximately $1,186,664,000 of the notes remaining outstanding. This action suggests a proactive approach to managing its debt obligations and capital structure.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Feb 23, 2026)
Centene Corporation (CNC) has filed an 8-K on February 23, 2026, primarily to disclose that its senior management team will be meeting with investors. During these meetings, the company intends to reaffirm its previously issued full-year 2026 guidance. This includes reiterating its GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its adjusted diluted EPS guidance of greater than $3.00. This reaffirmation suggests confidence in the company's financial trajectory for the remainder of the fiscal year, aligning with prior expectations despite potential market fluctuations. The filing also includes standard Forward-Looking Statements and a Non-GAAP Financial Presentation section. Centene emphasizes that its non-GAAP measures, which exclude items like amortization of acquired intangible assets and acquisition-related expenses, are provided to offer investors a clearer view of the ongoing operational performance and to facilitate more consistent period-to-period comparisons. Investors are advised to review GAAP financials in conjunction with these non-GAAP measures, as they may not be directly comparable to other companies' reporting.
CENTENE CORP 8-K Report, Financial Results (Feb 6, 2026)
Centene Corporation (CNC) has filed an 8-K on February 6, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. The filing primarily serves to attach the press release detailing these results and a presentation outlining the company's guidance for the full year 2026. Investors should refer to the attached exhibits (99.1 and 99.2) for the specific financial performance and forward-looking statements.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Nov 10, 2025)
Centene Corporation (CNC) has issued an 8-K filing on November 10, 2025, to announce its participation in the UBS 2025 Global Healthcare Conference on November 11, 2025. During this conference and subsequent investor discussions, management will provide commentary on the company's financial outlook. Importantly, this outlook remains consistent with the previously issued full-year 2025 guidance. Specifically, Centene reaffirms its full-year 2025 GAAP forecast of a diluted loss per share not exceeding $(12.85). Concurrently, the company reiterates its adjusted diluted EPS forecast for the full year 2025 to be at least $2.00. The filing also clarifies the company's use of non-GAAP financial measures, emphasizing their utility in assessing ongoing operations and performance consistency, while strongly encouraging investors to review their full GAAP financial statements. Centene also includes its standard forward-looking statements disclaimer, outlining various risks and uncertainties that could affect future performance.
CENTENE CORP 8-K Report, Financial Results (Oct 29, 2025)
Centene Corporation (CNC) has filed an 8-K report on October 29, 2025, to announce its financial results for the third quarter ended September 30, 2025. The key details of these results are provided in an attached press release (Exhibit 99.1). Investors should note that while this information is being disclosed, it is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same liability implications as a formally filed document. This filing serves as the primary vehicle for disseminating CNC's latest quarterly performance. Investors seeking specific financial metrics such as revenue, earnings per share, and any forward-looking guidance or management commentary will need to refer to the content of the Exhibit 99.1 press release. The company has chosen to report these results via a press release, which is standard practice for earnings announcements, and the 8-K serves to formally submit that release to the SEC.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Sep 11, 2025)
Centene Corporation (CNC) announced via an 8-K filing on September 11, 2025, that management will participate in the Deutsche Bank 2025 Healthcare Summit. During this presentation, the company reiterated its full-year 2025 adjusted diluted earnings per share (EPS) forecast of approximately $1.75. This confirms that current business performance through August is tracking in line with the company's prior guidance, providing a degree of stability for investors amidst ongoing market dynamics. The filing also provided context on the use of non-GAAP financial measures, emphasizing their utility in assessing ongoing operational performance and consistency across periods. While not providing specific reconciliations for the EPS forecast to GAAP measures, Centene highlighted that these non-GAAP figures, excluding items like amortization of acquired intangibles and acquisition-related expenses, offer a clearer view of core business operations. Investors are encouraged to review the full GAAP financial statements alongside these non-GAAP metrics.
CENTENE CORP 8-K Report, Executive Changes (Aug 15, 2025)
Centene Corporation (CNC) announced the resignation of Director Thomas R. Greco, effective August 22, 2025. Mr. Greco's departure is attributed to his increased professional commitments following his recent appointment as CEO of FleetPride, Inc., a privately-held company. Importantly, the company stated that his resignation is not due to any disagreements with Centene's management or Board of Directors regarding the company's operations, policies, or practices. This change will result in a reduction of the Board's size from ten to nine directors.
CENTENE CORP 8-K Report, Executive Changes (Aug 4, 2025)
Centene Corporation (CNC) announced a notable change in its Board of Directors with the immediate resignation of Director Wayne S. DeVeydt, effective August 1, 2025. The company explicitly stated that Mr. DeVeydt's departure was not due to any disagreements regarding the company's operations, policies, or practices. This development has led to a reduction in the size of the Board, now comprising ten directors.
CENTENE CORP 8-K Report, Financial Results (Jul 25, 2025)
Centene Corporation (CNC) has filed an 8-K report on July 25, 2025, to announce its financial results for the second quarter ended June 30, 2025. This filing primarily directs investors to the press release (Exhibit 99.1) for detailed information on the company's operational performance and financial condition during the quarter. While the 8-K itself does not contain the financial figures, it serves as the official notification of their release.
CENTENE CORP 8-K Report, Financial Results (Jul 1, 2025)
Centene Corporation (CNC) announced on July 1, 2025, through an 8-K filing, that it has withdrawn its previously issued 2025 GAAP and adjusted diluted earnings per share (EPS) guidance. This withdrawal includes all underlying guidance elements. The company has not provided any revised guidance in this filing. Investors should note that this is a significant change from prior expectations and will likely lead to increased scrutiny of the company's future performance and outlook. The reasons for the withdrawal of guidance are not detailed within the 8-K filing itself, but the full press release containing this information is incorporated by reference.
CENTENE CORP 8-K Report, Shareholder Vote Results (May 14, 2025)
Centene Corporation (CNC) filed an 8-K detailing the outcomes of its Annual Meeting of Stockholders held on May 13, 2025. The filing indicates strong shareholder support for the company's slate of directors, with all eleven nominees receiving a significant majority of the votes cast for their election to a one-year term. This outcome suggests continued confidence from investors in the current leadership and governance of the company. Furthermore, shareholders provided advisory approval for the company's executive compensation structure and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposed 2025 Stock Incentive Plan also received shareholder approval, indicating support for management's equity-based compensation strategies. Notably, two shareholder proposals related to climate change disclosure and reporting were not approved.
CENTENE CORP 8-K Report, Regulation FD Disclosure (May 6, 2025)
Centene Corporation (CNC) filed an 8-K on May 6, 2025, primarily to reaffirm its financial guidance for the full year 2025. The company's senior management will meet with investors and plans to confirm the previously provided guidance floors for both GAAP diluted Earnings Per Share (EPS) of greater than $6.19 and adjusted diluted EPS of greater than $7.25. This reaffirmation suggests management's confidence in the company's operational performance and ability to meet its financial targets for the year. The filing also elaborates on Centene's use of non-GAAP financial measures. The company emphasizes that these measures, which exclude items like amortization of acquired intangible assets and acquisition/divestiture related expenses, are provided to offer investors a clearer view of the ongoing operational performance and to facilitate more consistent period-to-period comparisons. While Centene believes these non-GAAP figures are valuable for understanding core business operations, it strongly encourages investors to review its full GAAP financial statements and filings, noting that non-GAAP measures may differ from those used by other companies.
CENTENE CORP 8-K Report, Financial Results (Apr 25, 2025)
Centene Corporation (CNC) has filed an 8-K report on April 25, 2025, to announce its financial results for the first quarter ended March 31, 2025. The key details of these results are contained within the press release attached as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any forward-looking guidance provided by the company for the upcoming periods. While the 8-K itself is brief and primarily serves as a notification of the press release, the attached exhibit is the critical document for understanding Centene's recent performance. The company is providing this information to comply with reporting requirements and ensure timely disclosure to the market. Investors should carefully review the press release for any changes in business trends, operational updates, or management commentary that could impact the company's valuation and future prospects.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 12, 2025)
Centene Corporation (CNC) has filed an 8-K to announce their participation in the Barclays 27th Annual Global Healthcare Conference on March 12, 2025. The primary takeaway for investors is the company's reaffirmation of its previously issued 2025 adjusted diluted earnings per share (EPS) annual guidance of greater than $7.25. This signals management's confidence in their financial performance for the upcoming year, despite the inherent risks and uncertainties associated with the healthcare industry and the company's operations. The filing also reiterates Centene's use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance. While the company believes these measures are valuable for investors, it also cautions that they may differ from those used by other companies and encourages a comprehensive review of all SEC filings. The forward-looking statements section highlights a broad range of potential risks and uncertainties that could impact future results, covering regulatory changes, competition, operational challenges, and economic conditions.
CENTENE CORP 8-K Report, Material Agreement (Mar 5, 2025)
Centene Corporation (CNC) has announced the execution of a new Senior Unsecured Credit Facility, replacing its previous credit agreement. This new facility totals $6 billion, comprising a $4 billion revolving credit facility and a $2 billion term loan facility, with a maturity date set for March 5, 2030. The company simultaneously terminated its existing credit agreement and repaid outstanding obligations, indicating a proactive refinancing effort. The new credit agreement provides Centene with significant financial flexibility, allowing for borrowings in multiple currencies and offering voluntary prepayments without penalty. Key covenants include a debt-to-capital ratio not exceeding 0.60:1.00, with a potential step-up to 0.65:1.00 following a material acquisition. The proceeds from the term loan were used for refinancing existing debt, transaction-related expenses, and general corporate purposes, including working capital. This move is likely aimed at optimizing Centene's capital structure and securing more favorable terms for its long-term financing.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 3, 2025)
Centene Corporation (CNC) filed an 8-K on March 4, 2025, primarily to disclose that its senior management will be meeting with investors. A key takeaway from this disclosure is the reaffirmation of the Company's previously issued 2025 full-year adjusted diluted earnings per share (EPS) guidance floor of greater than $7.25. This confirmation provides investors with continued confidence in the company's profitability outlook for the current year. The filing also emphasizes Centene's use of non-GAAP financial measures, such as excluding amortization of acquired intangible assets and acquisition/divestiture related expenses, to provide a clearer view of ongoing operational performance. While the company believes these measures offer meaningful insights for assessing consistent performance across periods, investors are encouraged to review the full GAAP financial statements and understand that these non-GAAP figures may differ from those presented by other companies. The company also noted the difficulty in reconciling its forward-looking adjusted EPS guidance to GAAP measures without unreasonable effort.
CENTENE CORP 8-K Report, Executive Changes (Feb 24, 2025)
Centene Corporation (CNC) announced a change to its Board of Directors, appointing Kenneth Tanji as a new independent director, effective February 20, 2025. The Board's size has been expanded to accommodate this appointment, and Mr. Tanji will serve on the Audit and Compliance Committee. This addition brings a wealth of financial expertise to the board, with Mr. Tanji's extensive background as a former CFO of Prudential Financial and his current roles on other public company boards and as a university professor. Investors should view this as a positive move to strengthen the board's oversight capabilities, particularly in financial matters. The appointment of Mr. Tanji, who has no stated arrangements or related party transactions with the company, is intended to enhance the board's collective experience and governance. His term as a director will run until the company's 2025 annual meeting of stockholders. The press release detailing this announcement is incorporated into the filing, providing further context for shareholders.
CENTENE CORP 8-K Report, Financial Results (Feb 4, 2025)
Centene Corporation (CNC) has filed an 8-K report on February 4, 2025, primarily to announce its financial results for the fourth quarter and the full year ended December 31, 2024. The core of this filing is the press release included as Exhibit 99.1, which provides the detailed financial performance metrics for the period. Investors should refer to this press release for specific figures regarding revenue, profitability, and other key operational indicators, as well as any forward-looking statements or guidance issued by the company. This 8-K serves as a crucial notification of the company's latest financial status. While the 8-K itself contains limited narrative, the attached press release is the primary source for understanding Centene's performance and outlook. Investors are advised to examine the press release carefully for any material changes or trends that could impact the company's valuation and future prospects. It's important to note that the information furnished in this 8-K and its exhibits is generally not considered 'filed' for regulatory purposes, meaning it doesn't trigger the same liabilities under Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated into other filings.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Dec 12, 2024)
Centene Corporation (CNC) has filed an 8-K on December 12, 2024, primarily to disclose its 2025 financial guidance and reaffirm its 2024 guidance. This filing indicates the company is providing forward-looking financial targets for the upcoming fiscal year, which is a key event for investors assessing the company's future performance and strategic direction. Investors should pay close attention to the details of this guidance, as it will shape expectations for revenue, profitability, and operational metrics throughout 2025. Additionally, Centene hosted a virtual investor day on the same date, providing a platform for deeper discussion and Q&A regarding their financial outlook and business strategies. The reaffirmation of 2024 guidance suggests confidence in achieving current year targets, while the new 2025 guidance will be critical for understanding the company's growth trajectory and potential challenges or opportunities.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Nov 13, 2024)
Centene Corporation (CNC) has filed an 8-K report on November 13, 2024, to disclose that its senior management team will be meeting with investors. During these meetings, the company intends to reaffirm its previously issued full-year 2024 adjusted diluted Earnings Per Share (EPS) guidance of greater than $6.80. This reaffirms their confidence in their operational performance and financial targets for the current fiscal year. Furthermore, Centene also plans to reiterate its positive outlook for the future by stating that the company expects to achieve growth in adjusted diluted EPS for 2025 and beyond. This forward-looking statement signals the company's strategic focus on sustained growth and profitability, aiming to provide investors with confidence in the company's long-term trajectory.
CENTENE CORP 8-K Report, Executive Changes (Nov 12, 2024)
Centene Corporation (CNC) announced a significant leadership transition via an 8-K filing on November 12, 2024. Kenneth J. Fasola, President of the company, has informed the Board of his intention to retire effective July 1, 2025. This announcement marks the end of Mr. Fasola's impactful 40-year career in healthcare, with a substantial portion spent at Centene. Leading up to his retirement, Mr. Fasola will focus on transitioning his current responsibilities to ensure a smooth handover of duties. Following this transition period, he will serve as a Strategic Advisor to the CEO, Sarah M. London, until his final retirement. This arrangement will allow Centene to leverage Mr. Fasola's extensive experience during this interim period. Investors should monitor the company's succession planning and the integration of Mr. Fasola's former duties by the executive team.
CENTENE CORP 8-K Report, Financial Results (Oct 25, 2024)
Centene Corporation (CNC) has filed an 8-K report on October 25, 2024, primarily to announce its third-quarter financial results for the period ending September 30, 2024. The details of these results are provided in a press release, which is included as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, operational achievements, and management's commentary on the quarter. This filing serves as the official notification of the Q3 2024 results. It's important for investors to note that the information within this 8-K and its attached press release is furnished and not filed, meaning it does not carry the same legal implications under Section 18 of the Securities Exchange Act of 1934. However, the press release itself contains the substantive financial information and outlook that investors will be analyzing to assess Centene's current performance and future prospects.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Oct 11, 2024)
Centene Corporation (CNC) announced an improvement in its 2025 Medicare Advantage Star Ratings, with approximately 46% of its Medicare Advantage membership now enrolled in plans rated 3.5 stars or higher. This marks a significant increase from the prior year's 23% and aligns with the company's internal expectations, even in the face of higher-than-industry-anticipated cut point changes by the Centers for Medicare and Medicaid Services (CMS). This progress in Star Ratings is crucial for Centene, as higher ratings directly impact revenue and future growth potential. The company is also pursuing an appeal with CMS regarding its TTY (Teletypewriter) results, indicating a proactive approach to addressing all potential rating factors. Investors should monitor Centene's ongoing efforts to improve its quality scores and the outcome of the TTY appeal, as these factors are material to the company's financial performance and competitive positioning in the Medicare Advantage market.
CENTENE CORP 8-K/A Report, Executive Changes (Oct 3, 2024)
Centene Corporation (CNC) filed an 8-K on October 3, 2024, primarily detailing a change in board committee appointments. Thomas R. Greco has been appointed to both the Governance Committee and the Compensation and Talent Committee of the Board. This filing does not appear to contain information regarding significant financial performance, strategic shifts, or executive departures that would materially impact investor outlook in the short term. Investors should note that committee appointments, while important for corporate governance, are typically administrative and do not signal immediate changes in operational strategy or financial results.
CENTENE CORP 8-K Report, Executive Changes (Sep 27, 2024)
Centene Corporation (CNC) filed an 8-K on September 27, 2024, to report a change in its Board of Directors. Director Lori J. Robinson has informed the company that she will not seek re-election at the upcoming 2025 Annual Meeting. This decision marks the end of her five-year tenure on the board. While this is a routine change, investors should note any potential implications for board composition and governance. The company expressed gratitude for Director Robinson's service, suggesting a positive departure. Investors may want to monitor future board appointments and any strategic shifts that could accompany leadership changes.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Sep 16, 2024)
Centene Corporation (CNC) has filed an 8-K to disclose information related to upcoming investor meetings and its financial guidance. The company will be meeting with investors on September 17, 2024, and presenting at the Bank of America 2024 Global Healthcare Conference on September 18, 2024. During these engagements, Centene expects to reaffirm its full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80. The filing also emphasizes Centene's use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance and to facilitate consistent period-to-period comparisons. The company believes these measures, which exclude items like amortization of acquired intangible assets and acquisition-related expenses, offer meaningful insights into its core business. However, Centene cautions investors that these non-GAAP measures may differ from those used by other companies and should be reviewed alongside GAAP financial information. A reconciliation of the 2024 adjusted diluted EPS guidance to the comparable GAAP measure is not provided due to the difficulty in predicting certain timing and amounts of non-recurring items.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Sep 10, 2024)
Centene Corporation (CNC) filed an 8-K on September 10, 2024, to disclose information from an investor meeting. The key takeaway for investors is the reaffirmation of the company's full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80. This indicates management's confidence in achieving its previously stated financial targets for the year. The filing also reiterates a shift in EPS realization from the third quarter (Q3) to the fourth quarter (Q4) of 2024, with Q3 adjusted diluted EPS projected to be between $1.31 and $1.41. The company further noted positive progress in improving its Medicare Advantage Stars program performance, a key area for future growth and revenue enhancement within its government-backed health insurance offerings.
CENTENE CORP 8-K Report, Executive Changes (Aug 15, 2024)
Centene Corporation (CNC) announced on August 15, 2024, a change in its Board of Directors, effective August 9, 2024. The Board has been expanded from 10 to 11 members with the appointment of Thomas Greco. Mr. Greco brings extensive executive leadership experience, having previously served as CEO of Advance Auto Parts, Inc. and CEO of Frito-Lay North America, a division of PepsiCo, Inc. His appointment is intended to leverage his significant operational and strategic expertise. Mr. Greco's background includes a 30-year tenure at PepsiCo in various leadership roles and current board service with Tapestry, Inc. and Sabra Dipping Company LLC. He will participate in the company's standard compensation program for non-employee directors. This appointment appears to be a strategic move to enhance board oversight and governance, with no undisclosed arrangements or related party transactions identified.
CENTENE CORP 8-K Report, Financial Results (Jul 26, 2024)
Centene Corporation (CNC) has filed an 8-K on July 26, 2024, to report its financial results for the second quarter ended June 30, 2024. The primary focus of this filing is the accompanying press release (Exhibit 99.1), which contains the detailed financial performance for the period. Investors should review this press release for specific figures related to revenue, earnings, and any forward-looking guidance or commentary provided by management. While this 8-K itself does not contain extensive operational details, it serves as the official notification of the release of the Q2 2024 earnings announcement. The press release is expected to offer insights into the company's performance across its various business segments, including Medicare, Medicaid, and the Health Insurance Marketplace, and may provide updates on strategic initiatives or market conditions impacting the company. Investors are advised to consult Exhibit 99.1 for the comprehensive financial data and management's perspective.
CENTENE CORP 8-K Report, Financial Results (Jul 23, 2024)
Centene Corporation (CNC) has filed an 8-K report on July 23, 2024, primarily addressing the finalization of 2023 risk adjustment transfers by the Centers for Medicare and Medicaid Services (CMS). Initially, Centene had recorded a $1.3 billion payable related to the 2023 benefit year. However, the final CMS determination resulted in a $0.0 billion receivable, leading to a significant positive financial impact for Centene. This favorable outcome is primarily due to a net outperformance from the 2023 risk adjustment calculation, partially offset by an increase in Minimum Medical Loss Ratio (MLR) payable and estimated other offsets from competitors' insolvencies. The company is also providing preliminary second quarter 2024 financial results, expecting GAAP diluted EPS of $2.16 and adjusted diluted EPS of $2.42. These figures include the positive impact of the 2023 risk adjustment outperformance. Centene expects to reaffirm its full-year 2024 guidance, with a floor of greater than $5.94 for GAAP diluted EPS and greater than $6.80 for adjusted diluted EPS. Investors should note that these are preliminary results for Q2 2024 and actual results may differ.
CENTENE CORP 8-K Report, Regulation FD Disclosure (May 29, 2024)
Centene Corporation (CNC) filed an 8-K on May 29, 2024, to provide updates ahead of their investor meetings and the Bernstein Strategic Decisions Conference. The company is expected to reaffirm its full-year 2024 guidance for adjusted diluted EPS to be greater than $6.80 and a consolidated health benefits ratio between 87.3% and 87.9%. While reaffirming guidance, Centene highlighted some key intra-quarter insights that warrant investor attention. Specifically, the company noted higher-than-expected claims receipts in April and early May for its Medicaid segment, signaling continued elevated medical costs in this area, although a significant portion of Medicaid rate changes are anticipated between July and October 2024. Conversely, Centene anticipates strong performance in its Marketplace segment for 2024, including favorable risk adjustment outperformance from 2023. The Medicare segment is performing as expected. Importantly, the company's adjusted diluted EPS guidance now incorporates an estimated $125 million provision for premium deficiency reserves related to 2025 Medicare Advantage bids, to be recognized in the fourth quarter of 2024.
CENTENE CORP 8-K Report, Shareholder Vote Results (May 16, 2024)
Centene Corporation (CNC) filed an 8-K on May 16, 2024, detailing the results of its Annual Meeting of Stockholders held on May 14, 2024. The meeting saw significant participation, with over 495 million shares of common stock represented. Key outcomes include the overwhelming election of all ten director nominees for a one-year term, demonstrating strong shareholder confidence in the current board. Additionally, the company's executive compensation plan received a non-binding advisory vote of approval, signaling shareholder support for the compensation structure. The filing also confirmed the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, a routine but important governance step. However, a shareholder proposal related to managing climate risk through science-based targets and transition planning was not approved, receiving a majority of 'against' votes. These results collectively provide insights into shareholder sentiment on board leadership, executive pay, and specific environmental governance issues.
CENTENE CORP 8-K Report, Financial Results (Apr 26, 2024)
Centene Corporation (CNC) filed an 8-K on April 26, 2024, primarily to report its financial results for the first quarter ended March 31, 2024, via an attached press release (Exhibit 99.1). While the filing itself doesn't contain detailed financial figures, it signals the company's public disclosure of its Q1 performance. Investors should refer to the press release for specific operational and financial data, including revenue, earnings, and any forward-looking guidance provided by the company. This report serves as the official notification of the Q1 2024 earnings announcement. Investors will be looking for updates on key performance indicators, such as membership growth, medical loss ratios, and profitability across its various business segments, particularly its government-sponsored health plans (Medicaid and Medicare). Any strategic initiatives or challenges discussed in the press release will also be of significant interest to the market.
CENTENE CORP 8-K Report, Executive Changes (Mar 29, 2024)
Centene Corporation (CNC) filed an 8-K on March 29, 2024, to announce the retirement of James E. Murray, effective March 29, 2024. This departure aligns with Mr. Murray's previously disclosed intention to retire in 2024, as communicated in a prior 8-K filing on May 22, 2023. Investors should note that this retirement was anticipated and is not indicative of any new, unexpected leadership changes or strategic shifts at this time.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 11, 2024)
Centene Corporation (CNC) issued an 8-K filing on March 11, 2024, to announce participation in the Barclays 26th Annual Global Healthcare Conference on March 12, 2024. The primary purpose of this disclosure is to reaffirm the company's previously issued 2024 adjusted diluted earnings per share (EPS) guidance, which is expected to be greater than $6.70. This reaffirmation provides investors with continued confidence in the company's near-term earnings outlook. The filing also details Centene's rationale for presenting non-GAAP financial measures, emphasizing their utility in assessing ongoing operations and performance consistency, while cautioning investors to consider these alongside GAAP figures and acknowledging the difficulty in reconciling forward-looking non-GAAP guidance to GAAP measures.
CENTENE CORP 8-K Report, Financial Results (Feb 6, 2024)
Centene Corporation (CNC) filed an 8-K on February 6, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The key details of these results are provided in the accompanying press release, which is furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, earnings, and any forward-looking guidance or commentary provided by the company. While the 8-K itself is brief and primarily serves to attach the press release, the press release is the critical document for understanding Centene's recent performance and outlook. Investors are advised to carefully review the press release for details on the company's operational performance, strategic initiatives, and any significant events or factors that may have impacted its financial condition during the reporting period and beyond.
CENTENE CORP 8-K Report, Bylaw Amendment (Dec 13, 2023)
Centene Corporation (CNC) has filed an 8-K report on December 13, 2023, detailing amendments to its Amended and Restated By-Laws, effective December 8, 2023. The primary focus of these amendments is to enhance and clarify the procedural and disclosure requirements for stockholders seeking to call special meetings or propose business and nominations at annual or special meetings. These changes are designed to ensure greater transparency and compliance with corporate governance standards. Specifically, the amendments address the ownership threshold and timing for calling special meetings, as well as refine the notification process for director nominations and business proposals. Enhanced disclosure requirements will now mandate more detailed information about the nominating stockholder, their nominees, and associates, ensuring accuracy and timeliness. Furthermore, the by-laws now explicitly require stockholders intending to solicit support for director nominations to provide representations and evidence of compliance with Rule 14a-19. These updates aim to provide a clearer framework for shareholder engagement and align the company's governance practices with the Delaware General Corporation Law.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Dec 12, 2023)
Centene Corporation (CNC) announced its 2024 financial guidance and reaffirmed its 2023 guidance for premium and service revenues, Health Benefits Ratio (HBR), and adjusted diluted earnings per share (EPS) in a press release dated December 12, 2023. The company also revealed that its Board of Directors has approved a significant $4.0 billion increase to its existing stock repurchase program, bringing the total available under the program to approximately $5.23 billion. These announcements were made in conjunction with Centene's investor day event, hosted by CEO Sarah London and other management team members, providing a platform for detailed discussion and outlook. Investors should pay close attention to the specific 2024 guidance metrics as they become available, as these will shape expectations for the company's performance in the upcoming fiscal year. The substantial increase in the stock repurchase authorization signals management's confidence in the company's financial position and its commitment to returning capital to shareholders. This event and the associated disclosures are critical for understanding Centene's strategic direction and financial trajectory.
CENTENE CORP 8-K Report, Executive Changes (Nov 15, 2023)
Centene Corporation (CNC) has announced a significant leadership change, appointing Susan Smith as its new Chief Operating Officer, effective January 1, 2024. Ms. Smith brings extensive experience from her 19-year tenure at Humana Inc., where she held senior leadership roles with broad oversight of clinical strategy, operations, quality, and Medicare solutions. This appointment signals a strategic move to bolster operational leadership with a seasoned executive from within the managed care industry. Investors should note Ms. Smith's compensation package, which includes a base salary of $700,000, an annual short-term incentive target of $700,000, and a substantial annual long-term equity incentive target of $1,600,000. This compensation structure aligns with typical arrangements for senior executives and underscores the company's investment in key leadership. The filing also confirms no unusual arrangements or conflicts of interest related to Ms. Smith's appointment.
CENTENE CORP 8-K Report, Financial Results (Oct 24, 2023)
Centene Corporation (CNC) filed an 8-K on October 24, 2023, primarily to announce its financial results for the third quarter ended September 30, 2023. The core of the announcement is contained within the press release furnished as Exhibit 99.1. Investors should refer to this press release for detailed financial performance information, as the 8-K itself is largely a notification of this release and does not contain the substantive financial data. While the 8-K does not provide the specific figures, it signals that Centene has reported its Q3 2023 earnings. Investors interested in the company's performance, including revenue, earnings per share, and any forward-looking guidance or commentary on operational trends, will need to access the referenced press release. The filing also notes that the information is furnished and not deemed 'filed' under specific SEC regulations, a standard disclosure for such announcements.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Oct 16, 2023)
Centene Corporation (CNC) has announced its 2024 Medicare Advantage Star Ratings results, which were recently published by the Centers for Medicare and Medicaid Services (CMS). The company reported that approximately 73% of its membership is associated with contracts that showed year-over-year unrounded score improvement. Furthermore, a significant 87% of its membership is now in contracts rated 3.0 stars or better, a notable increase from 53% in the prior year. These figures align closely with management's previous public targets, indicating progress towards the company's multi-year goals for enhancing its Star ratings, which are crucial for revenue and continued growth in its Medicare Advantage business.
CENTENE CORP 8-K Report, Regulation FD Disclosure (Sep 6, 2023)
Centene Corporation (CNC) filed an 8-K on September 6, 2023, to disclose information presented at the Wells Fargo 2023 Healthcare Conference. The primary takeaway for investors is that the company reaffirmed its full-year 2023 Adjusted Diluted Earnings Per Share (EPS) guidance, projecting at least $6.45, which includes results from July. This reaffirmation indicates management's confidence in the company's current performance trajectory and its ability to meet previously stated financial targets. Furthermore, Centene also reiterated its 2024 Adjusted Diluted EPS floor guidance, stating it expects earnings to be greater than $6.60. This forward-looking statement provides investors with visibility into the company's expectations for the following fiscal year, suggesting continued positive momentum and a commitment to growing shareholder value. The webcast and its replay offer further details, but these guidance reaffirmations are the most critical points for immediate investor assessment.
CENTENE CORP 8-K Report, Financial Results (Jul 28, 2023)
Centene Corporation (CNC) filed an 8-K on July 28, 2023, primarily to furnish its second-quarter 2023 earnings press release. While the filing itself is brief and contains no new financial data beyond what was disclosed in the press release, it signals that the company has provided an update on its operational and financial performance. Investors should refer to the press release (Exhibit 99.1) for detailed insights into the company's results, as this 8-K does not offer further analysis or context. Key information regarding revenue, profitability, segment performance, and forward-looking guidance would be found within the press release. This filing serves as the official notification of the release of that information and allows the market to react to Centene's latest financial disclosures. Investors are encouraged to review the press release directly for a comprehensive understanding of Centene's second-quarter performance and its implications.